Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% Days Payable is 14.04 as of Mar. 2026, which is 93% below its 10-year median of 212.92. The stock has 1 warning sign investors should review. Among 190 Medical Diagnostics & Research companies, Invitro International ranks worse than 95.26% on this metric.
Invitro International Days Payable Historical Data
* Premium members only.
The historical data trend for Invitro International's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Days Payable distribution charts can be found below:
* The bar in red indicates where Invitro International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Invitro International's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International (IVRO) has a Days Payable of 14.04 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invitro International and its competitors. This is 93% below median its historical median of 212.92. Over the past decade, Invitro International's Days Payable has ranged from 5.67 to 669.17. According to the industry distribution chart, Invitro International ranks #181 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 95.3%.
Is Invitro International's Days Payable too high?
Invitro International's current Days Payable of 14.04 is 93% below median its 10-year median of 212.92. Over the past 10 years, this metric has ranged from a low of 5.67 to a high of 669.17. The Medical Diagnostics & Research industry median Days Payable is 64.64. Invitro International's value of 14.04 is 78.3% below this industry median. Based on the distribution chart, Invitro International ranks #181 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Invitro International's Days Payable compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #181 out of 190 companies for Days Payable. This places Invitro International in the lower half of its industry. The industry median Days Payable is 64.64. Invitro International's value of 14.04 is 78.3% below this benchmark. Historically, Invitro International's own Days Payable has ranged from 5.67 to 669.17 over the past decade. While the company's 10-year median is 212.92 vs. the industry median of 64.64, Invitro International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current Days Payable of 14.04 is 78.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current Days Payable is 14.04, which is 93% below median its own 10-year median of 212.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Days Payable is 14.04, which is 93% below median its 10-year median of 212.92 and 78.3% below the Medical Diagnostics & Research industry median of 64.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Invitro International (IVRO), the current Days Payable is 14.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
